enGene interim CMO William Grossman acquires common shares worth $10,050.94

Bitget2026/09/24 20:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

William Grossman, interim chief medical officer, bought 5,102 enGene Therapeutics common shares at USD 1.97 each.
Post-transaction stake rose to 5,102 common shares, held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001552781-26-000501), on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Indian regulators announced on Thursday that they will allow the country’s $463 billion portfolio management industry to invest in overseas securities for the first time and to conduct short-selling in stock options. This move opens up new channels for India’s wealthy class to access global markets and holds significance for AI-related assets, which have attracted strong investor interest. Additionally, India will launch new portfolio management products with lower investment thresholds.

华尔街见闻•2026/09/24 21:16